VYNE Therapeutics (VYNE) Short Interest Ratio & Short Volume $1.84 -0.02 (-1.08%) Closing price 04/23/2025 04:00 PM EasternExtended Trading$1.82 -0.02 (-0.82%) As of 04/23/2025 05:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VYNE Therapeutics Short Interest DataVYNE Therapeutics (VYNE) has a short interest of 135,700 shares, representing 1.07% of the float (the number of shares available for trading by the public). This marks a -9.83% decrease in short interest from the previous month. The short interest ratio (days to cover) is 1.0, indicating that it would take 1.0 days of the average trading volume of 87,500 shares to cover all short positions.Current Short Interest135,700 sharesPrevious Short Interest150,500 sharesChange Vs. Previous Month-9.83%Dollar Volume Sold Short$214,406.00Short Interest Ratio1.0 Days to CoverLast Record DateMarch 31, 2025Outstanding Shares15,210,000 sharesFloat Size12,680,000 sharesShort Percent of Float1.07%Today's Trading Volume60,243 sharesAverage Trading Volume87,500 sharesToday's Volume Vs. Average69% Short Selling VYNE Therapeutics? Sign up to receive the latest short interest report for VYNE Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartVYNE Short Interest Over TimeVYNE Days to Cover Over TimeVYNE Percentage of Float Shorted Over Time VYNE Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/31/2025135,700 shares $214,406.00 -9.8%1.1%1 $1.58 3/15/2025150,500 shares $278,425.00 +21.6%1.2%1.3 $1.85 2/28/2025123,800 shares $311,976.00 -11.4%1.0%1.2 $2.52 2/15/2025139,800 shares $345,306.00 +13.5%1.1%1.4 $2.47 1/31/2025123,200 shares $289,520.00 +9.7%1.0%1.1 $2.35 1/15/2025112,300 shares $309,948.00 +82.9%0.9%1 $2.76 12/31/202461,400 shares $205,690.00 -1.6%0.5%0.5 $3.35 12/15/202462,400 shares $159,744.00 -3.0%0.5%0.7 $2.56 11/30/202464,300 shares $190,328.00 -37.1%0.5%0.8 $2.96 11/15/2024102,200 shares $275,940.00 +23.7%0.8%1.3 $2.70 Get the Latest News and Ratings for VYNE and Related StocksEnter your email address below to receive the latest news and analysts' ratings for VYNE Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 10/31/202482,600 shares $224,672.00 +65.2%0.7%1.2 $2.72 10/15/202450,000 shares $100,000.00 -14.1%0.4%1 $2.00 9/30/202458,200 shares $109,416.00 +75.8%0.5%1.3 $1.88 9/15/202433,100 shares $60,904.00 -28.8%0.3%0.7 $1.84 8/31/202446,500 shares $84,630.00 -20.0%0.4%0.9 $1.82 8/15/202458,100 shares $108,066.00 -13.0%0.5%1.1 $1.86 7/31/202466,800 shares $126,920.00 +8.1%0.5%1.3 $1.90 7/15/202461,800 shares $139,050.00 +10.6%0.5%1.1 $2.25 6/30/202455,900 shares $110,123.00 -10.9%0.5%1 $1.97 6/15/202462,700 shares $144,210.00 +22.2%0.5%0.7 $2.30 5/31/202451,300 shares $130,302.00 -10.6%0.4%0.6 $2.54 5/15/202457,400 shares $160,720.00 -30.0%0.5%0.6 $2.80 4/30/202482,000 shares $206,640.00 -15.3%0.7%0.8 $2.52 4/15/202496,800 shares $248,776.00 +13.1%0.8%0.9 $2.57 3/31/202485,600 shares $262,792.00 +590.3%0.7%0.7 $3.07 3/15/202412,400 shares $24,924.00 -63.4%0.1%0.1 $2.01 2/29/202433,900 shares $75,597.00 -5.3%0.3%0.3 $2.23 2/15/202435,800 shares $77,328.00 -31.8%0.3%0.4 $2.16 1/31/202452,500 shares $89,775.00 -40.3%0.4%0.5 $1.71 1/15/202488,000 shares $181,280.00 No Change0.7%0.2 $2.06 12/31/202388,000 shares $205,040.00 +1,157.1%N/A0.2 $2.33 12/15/20237,000 shares $19,180.00 -94.4%0.1%0 $2.74 11/30/2023124,800 shares $413,088.00 -15.0%1.0%0.4 $3.31 11/15/2023146,800 shares $604,816.00 +150.9%1.2%0.4 $4.12 10/31/202358,500 shares $178,425.00 +11.6%1.9%0.2 $3.05 10/15/202352,400 shares $144,100.00 -7.6%1.7%3.3 $2.75 9/30/202356,700 shares $229,068.00 -8.1%1.8%3.5 $4.04 9/15/202361,700 shares $237,545.00 -0.2%2.0%4.1 $3.85 8/31/202361,800 shares $268,830.00 -19.7%2.0%3.7 $4.35 8/15/202377,000 shares $373,450.00 +13.1%2.4%3.7 $4.85Silicon Valley Gold Rush (Ad)A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free.Gates and Altman are betting big—see why 7/31/202368,100 shares $316,665.00 +3.8%2.2%2 $4.65 7/15/202365,600 shares $276,832.00 -6.0%2.1%0.7 $4.22 6/30/202369,800 shares $286,180.00 -5.6%2.2%0.1 $4.10 6/15/202373,900 shares $352,281.30 +13.7%2.4%0.1 $4.77 5/31/202365,000 shares $408,850.00 -29.3%2.1%0.1 $6.29 5/15/202391,900 shares $705,792.00 -55.6%2.9%0.1 $7.68 4/30/2023206,800 shares $1.09 million +119.1%6.6%0.3 $5.26 4/15/202394,400 shares $256,768.00 -3.9%3.0%0.1 $2.72 3/31/202398,200 shares $302,456.00 +30.2%3.1%1.7 $3.08 3/15/202375,400 shares $192,270.00 +38.1%2.3%1 $2.55 2/28/202354,600 shares $182,091.00 -2.5%1.7%0.8 $3.34 2/15/202356,000 shares $196,560.00 -94.6%1.8%0.8 $3.51 1/31/20231,030,000 shares $267,800.00 -29.0%N/A0.8 $0.26 1/15/20231,450,000 shares $388,311.45 +105.2%N/A1.2 $0.27 12/30/2022706,800 shares $106,020.00 -7.4%N/A0.6 $0.15 12/15/2022763,400 shares $129,472.64 -4.3%N/A3.5 $0.17 11/30/2022797,700 shares $185,545.02 +3.5%N/A4.3 $0.23 11/15/2022770,600 shares $189,297.89 -3.6%N/A4.3 $0.25 10/31/2022799,300 shares $204,301.08 +3.2%N/A2.7 $0.26 10/15/2022774,400 shares $187,792.00 +0.0%N/A2.6 $0.24 9/30/2022774,200 shares $172,724.02 -22.4%N/A2.6 $0.22 9/15/2022997,900 shares $282,405.70 +48.9%N/A3.1 $0.28 8/31/2022670,200 shares $209,973.66 -6.0%N/A1.9 $0.31 8/15/2022713,200 shares $228,224.00 -4.9%N/A1.9 $0.32 7/31/2022750,300 shares $324,204.63 -15.5%N/A2.5 $0.43 7/15/2022887,400 shares $399,330.00 -22.8%N/A2.6 $0.45 6/30/20221,150,000 shares $447,350.00 -9.5%N/A2 $0.39 6/15/20221,270,000 shares $660,400.00 +5.0%N/A2 $0.52 5/31/20221,210,000 shares $492,954.00 -11.7%N/A1.8 $0.41 5/15/20221,370,000 shares $545,260.00 -12.7%N/A2 $0.40 4/30/20221,570,000 shares $659,400.00 +8.3%N/A2.1 $0.42 4/15/20221,450,000 shares $767,050.00 +57.0%N/A1.7 $0.53 3/31/2022923,800 shares $600,562.38 -19.0%N/A0.8 $0.65 3/15/20221,140,000 shares $638,400.00 -22.5%N/A1 $0.56 2/28/20221,470,000 shares $796,740.00 -6.4%N/A0.5 $0.54 2/15/20221,570,000 shares $893,487.00 -23.4%N/A0.6 $0.57 1/31/20222,050,000 shares $1.27 million +12.6%N/A0.7 $0.62 1/15/20221,820,000 shares $1.25 million -12.5%N/A0.7 $0.69 12/31/20212,080,000 shares $2.12 million -34.0%N/A0.9 $1.02 12/15/20213,150,000 shares $3.59 million +283.4%N/A1.3 $1.14 11/30/2021821,600 shares $846,248.00 -11.7%N/A0.6 $1.03 11/15/2021930,900 shares $1.19 million +5.5%N/A1.3 $1.28 10/29/2021882,000 shares $1.18 million +1.5%1.7%1 $1.34 10/15/2021869,400 shares $1.06 million -9.6%1.7%1 $1.22 9/30/2021962,100 shares $1.34 million -23.0%1.9%1.3 $1.39 9/15/20211,250,000 shares $1.85 million -11.4%2.5%1.5 $1.48 8/31/20211,410,000 shares $2.40 million -50.4%2.8%1.6 $1.70 8/13/20212,840,000 shares $5.06 million -6.6%5.6%3.2 $1.78 7/30/20213,040,000 shares $8.21 million +7.8%6.0%4.1 $2.70 7/15/20212,820,000 shares $7.76 million +9.7%5.6%3.2 $2.75Silicon Valley Gold Rush (Ad)A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free.Gates and Altman are betting big—see why 6/30/20212,570,000 shares $9.02 million -35.6%5.1%2.8 $3.51 6/15/20213,990,000 shares $14.52 million -1.2%7.9%4.6 $3.64 5/28/20214,040,000 shares $15.96 million -7.3%8.0%4.6 $3.95 5/14/20214,360,000 shares $14.13 million +15.7%8.6%4.4 $3.24 4/30/20213,770,000 shares $19.34 million +13.2%7.5%2.5 $5.13 4/15/20213,330,000 shares $18.78 million -0.9%6.6%1.4 $5.64 3/31/20213,360,000 shares $22.14 million +14.7%6.7%1.4 $6.59 3/15/20212,930,000 shares $21.65 million +7.7%5.8%1.3 $7.39 2/26/20212,720,000 shares $21.46 million -71.8%5.4%1.2 $7.89 2/12/20219,660,000 shares $102.78 million -7.9%19.7%4.8 $10.64 1/29/202110,490,000 shares $93.57 million +15.2%5.8%1.6 $8.92 1/15/20219,110,000 shares $60.13 million No Change5.7%2.4 $6.60 8/14/20209,960,000 shares $64.14 million -3.7%N/A2.2 $6.44 7/31/202010,340,000 shares $66.59 million +19.0%N/A2.1 $6.44 7/15/20208,690,000 shares $56.31 million -22.7%N/A1.7 $6.48 6/30/202011,240,000 shares $81.38 million +62.0%N/A2.1 $7.24 6/15/20206,940,000 shares $61.07 million +44.9%N/A1.4 $8.80 5/29/20204,790,000 shares $45.79 million +20.1%N/A1.2 $9.56 5/15/20203,990,000 shares $26.97 million -29.6%N/A1.4 $6.76 4/30/20205,670,000 shares $41.28 million +9.7%N/A2.8 $7.28 VYNE Short Interest - Frequently Asked Questions What is VYNE Therapeutics' current short interest? Short interest is the volume of VYNE Therapeutics shares that have been sold short but have not yet been closed out or covered. As of March 31st, investors have sold 135,700 shares of VYNE short. 1.07% of VYNE Therapeutics' shares are currently sold short. Learn More on VYNE Therapeutics' current short interest. What is a good short interest ratio for VYNE Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. VYNE shares currently have a short interest ratio of 1.0. Learn More on VYNE Therapeutics's short interest ratio. Which institutional investors are shorting VYNE Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of VYNE Therapeutics: Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for VYNE Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 1.07% of VYNE Therapeutics' floating shares are currently sold short. Is VYNE Therapeutics' short interest increasing or decreasing? VYNE Therapeutics saw a decrease in short interest in March. As of March 31st, there was short interest totaling 135,700 shares, a decrease of 9.8% from the previous total of 150,500 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is VYNE Therapeutics' float size? VYNE Therapeutics currently has issued a total of 15,210,000 shares. Some of VYNE Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. VYNE Therapeutics currently has a public float of 12,680,000 shares. How does VYNE Therapeutics' short interest compare to its competitors? 1.07% of VYNE Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to VYNE Therapeutics: Fate Therapeutics, Inc. (15.13%), Enanta Pharmaceuticals, Inc. (13.47%), Tonix Pharmaceuticals Holding Corp. (13.37%), SELLAS Life Sciences Group, Inc. (11.76%), Contineum Therapeutics, Inc. (5.11%), Alector, Inc. (7.26%), Kyverna Therapeutics, Inc. (15.01%), XBiotech Inc. (3.97%), Tiziana Life Sciences Ltd (1.05%), Oramed Pharmaceuticals Inc. (1.87%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($21.93 billion), iShares 20+ Year Treasury Bond ETF ($9.31 billion), Strategy Incorporated ($8.42 billion), Charter Communications, Inc. ($4.52 billion), Apollo Global Management, Inc. ($4.26 billion), Super Micro Computer, Inc. ($3.98 billion), Capital One Financial Co. ($3.79 billion), TC Energy Co. ($3.43 billion), AppLovin Co. ($2.91 billion), and Schlumberger Limited ($2.89 billion). View all of the most shorted stocks. What does it mean to sell short VYNE Therapeutics stock? Short selling VYNE is an investing strategy that aims to generate trading profit from VYNE Therapeutics as its price is falling. VYNE shares are trading down $0.02 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against VYNE Therapeutics? A short squeeze for VYNE Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of VYNE, which in turn drives the price of the stock up even further. How often is VYNE Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including VYNE, twice per month. The most recent reporting period available is March, 31 2025. More Short Interest Resources from MarketBeat Related Companies Fate Therapeutics Short Interest Data Enanta Pharmaceuticals Short Interest Data Tonix Pharmaceuticals Short Interest Data SELLAS Life Sciences Group Short Interest Data Contineum Therapeutics Short Interest Data Alector Short Interest Data Kyverna Therapeutics Short Interest Data XBiotech Short Interest Data Tiziana Life Sciences Short Interest Data Oramed Pharmaceuticals Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:VYNE) was last updated on 4/24/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredM.A.G.A. is Finished – This Could be even BetterYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...Paradigm Press | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredThe Exact July Date the AI Correction Will End?AI stocks have cooled off—but Jeff Brown, the tech expert who picked Nvidia before it soared 222x, says one da...Brownstone Research | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredTrump’s treachery Forget what the media tells you. Trump’s inner circle may be pushing a financial reset that mirrors moves from...Porter & Company | SponsoredThe Last Time This Happened, Americans Lost BillionsWall Street leaders just held a secret meeting in Las Vegas. What they discussed mirrors 2006 — and the warnin...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VYNE Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share VYNE Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VYNE Stock Free VYNE Stock Alerts